CPSE:GMAB
CPSE:GMABBiotechs

Genmab’s Valuation in Focus After Recent Pipeline Collaboration and Price Swings

If you are eyeing Genmab’s stock right now, you are certainly not alone. After a sharp 6.2% rally over the past month, the stock has given up some of those gains with a -9.2% slip in the last week. But don’t let short-term swings distract you from the surprising longer-term resilience here. Genmab is still up 26.6% since January and has gained 22.8% over the past year, even as the wider biotech sector has had its share of shake-ups. What is driving all this movement? It has been a mix of...
CPSE:EMBLA
CPSE:EMBLAMedical Equipment

Embla Medical hf (CPSE:EMBLA) Trades Below Fair Value as Profit Margin Improves, Reinforcing Bullish Outlook

Embla Medical hf (CPSE:EMBLA) posted earnings forecast to grow at 14.51% per year, with revenue set to rise by 8.5% annually. Both figures are ahead of the Danish market’s expected growth. The company’s net profit margin edged up to 8.6% from 8.2% the year before. While the most recent year’s earnings growth came in at 11.7%, the broader five-year average sits at a robust 19.2% per year. Embla’s combination of faster-than-market growth and steadily improving profitability, coupled with a lack...
CPSE:DANSKE
CPSE:DANSKEBanks

Is Danske Bank Still a Bargain After Surging 50% on Legal Resolution?

If you’ve been paying attention to Danske Bank lately, you’ve probably noticed there’s been plenty of action in its share price. Maybe you’re even wondering whether now is the moment to jump in or take some profits off the table. Over the past year, Danske Bank has delivered a remarkable 50.2% return, with gains standing at a powerhouse 230.9% for the past three years and nearly tripling over five years. Even in the shorter term, its year-to-date return is a striking 33.8%. While the 7-day...
CPSE:ROCK B
CPSE:ROCK BBuilding

How Investors Are Reacting To Rockwool (CPSE:ROCK B) as Asia-Pacific Mineral Wool Exports Surge 37%

Recently released data indicates the Asia-Pacific mineral wool market is projected to grow at a 1.3% CAGR, reaching 15 million tons by 2035, with China accounting for nearly half of regional consumption and production, and Japan leading in market value. An especially large 37% increase in regional exports during 2024, driven primarily by China, highlights accelerating trade activity and solidifies the region’s growing importance for mineral wool producers like Rockwool. With rising...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Coloplast (CPSE:COLO B) Valuation in Focus as Leadership Transition Signals New Strategic Direction

Coloplast (CPSE:COLO B) has announced that interim CEO Lars Rasmussen will not stand for re-election to the Board at the upcoming annual general meeting in December. The search for a permanent CEO continues. See our latest analysis for Coloplast. Leadership shifts like these tend to put a spotlight on Coloplast’s next chapter, which investors are weighing against a challenging year. While recent days saw a modest 3.54% 7-day share price return, the 1-year total shareholder return has slumped...
CPSE:CHEMM
CPSE:CHEMMLife Sciences

Does ChemoMetec's (CPSE:CHEMM) Dividend Highlight a Conservative Approach to Capital Allocation?

At its Annual General Meeting held on 9 October 2025, ChemoMetec A/S approved a dividend distribution of DKK 7 per share of nominal value DKK 1. This move highlights the company's focus on returning capital to shareholders and may signal confidence in its ongoing financial stability. We'll explore how the approved dividend underscores ChemoMetec's shareholder priorities and affects its overall investment narrative. Find companies with promising cash flow potential yet trading below their...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Could Novo Nordisk’s (CPSE:NOVO B) Rare Disease Bet Shift Its Portfolio Beyond Diabetes?

Omeros Corporation recently announced a definitive asset purchase and license agreement granting Novo Nordisk exclusive global rights to develop and commercialize zaltenibart, an experimental antibody targeting rare blood and kidney disorders, in exchange for US$340 million upfront and potential total payments of up to US$2.1 billion plus tiered royalties. This deal marks Novo Nordisk's significant move to diversify its portfolio beyond diabetes and obesity by investing in promising...
CPSE:DSV
CPSE:DSVLogistics

Ransomware Attack Highlights Evolving Cyber Risks for DSV (CPSE:DSV) and Global Logistics

In early October 2025, DSV A/S was named as a victim of a ransomware attack by a new hacking group called the Coinbase Cartel, which specifically targets logistics companies through data exfiltration and extortion tactics. This incident highlights the elevated and evolving cybersecurity risks facing global supply chain operators and the logistics industry as a whole. We will examine how these rising cybersecurity concerns, punctuated by the recent ransomware attack, may alter DSV's...
CPSE:DSV
CPSE:DSVLogistics

DSV (CPSE:DSV) Valuation in Focus Following Ransomware Attack on Logistics Sector

Recent reports have surfaced about DSV (CPSE:DSV) being targeted by a new hacking group that is focused on logistics companies. The ransomware claim highlights ongoing cybersecurity challenges for firms in the supply chain sector. See our latest analysis for DSV. DSV’s latest news comes after a challenging period for shareholders. While the company recently presented at the Xeneta Summit in Barcelona, its share price return year-to-date stands at -16.08%, and the past year’s total shareholder...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Is Now the Right Time to Consider Maersk After Its Recent Share Price Slide?

If you're eyeing A.P. Møller - Mærsk and asking yourself whether now is the right time to buy, sell or just hang tight, you are certainly not alone. While many stocks have been doing a bit of a dance recently, Mærsk has shown its share of interesting moves that should catch the attention of any investor. In the short term, the share price has dipped, dropping 1.4% over the last week and 6.8% in the past month. But zoom out, and it is a very different story. The stock has climbed an impressive...
CPSE:VWS
CPSE:VWSElectrical

A Look at Vestas (CPSE:VWS) Valuation Following Latest European Wind Turbine Orders

Vestas Wind Systems (CPSE:VWS) just shared news of a series of firm wind turbine orders, covering Germany, Italy, Denmark, and the United Kingdom. This steady stream of deals highlights the company’s momentum in Europe’s clean energy transition. See our latest analysis for Vestas Wind Systems. After a challenging period, Vestas Wind Systems' latest wave of turbine deals is helping to reignite optimism. This is reflected in a 13.2% 1-month share price return and a 21.5% gain over the past 90...
CPSE:VWS
CPSE:VWSElectrical

Why Vestas (CPSE:VWS) Is Up 6.5% After Surge in Major European Wind Turbine Orders

Vestas Wind Systems recently announced a surge in firm wind turbine orders across Europe, including over 239 MW in Germany, 346 MW spanning Germany, Denmark, and the UK, and 94 MW in Italy, featuring its latest EnVentus platform technology and long-term service agreements. This rapid expansion in order intake underscores growing customer confidence in Vestas' advanced solutions and highlights robust momentum for renewable energy projects in key European markets. We’ll examine how these...
CPSE:RBREW
CPSE:RBREWBeverage

Royal Unibrew (CPSE:RBREW) Share Buy-Back Sparks Fresh Look at Company Valuation

Royal Unibrew (CPSE:RBREW) has kicked off a share buy-back program, beginning August 27 and running until December 19, 2025. This move typically indicates management’s confidence in the company and can influence investor attitudes. See our latest analysis for Royal Unibrew. Despite Royal Unibrew’s new buy-back program hinting at management’s confidence, the stock has lost some momentum lately. Over the past year, the total shareholder return was -7.9%, while the three-year gain was 7.7%,...
CPSE:PNDORA
CPSE:PNDORALuxury

Succession Plan May Change the Case for Investing in Pandora (CPSE:PNDORA)

Pandora announced that CEO Alexander Lacik will retire at the next annual general meeting in March 2026, with Chief Marketing Officer Berta de Pablos-Barbier set to succeed him following her influential role in the company’s brand transformation since November 2024. This leadership transition follows a period of substantial revenue expansion and workforce growth, with de Pablos-Barbier’s deep experience across luxury and consumer goods expected to support Pandora’s continued evolution as a...
CPSE:ORSTED
CPSE:ORSTEDRenewable Energy

The Bull Case For Ørsted (CPSE:ORSTED) Could Change Following Major Rights Offering and Strategic Refocus

Ørsted recently completed a major rights offering, raising DKK 59.99 billion by issuing over 900 million shares and announced plans to cut approximately 2,000 jobs, as it focuses on European offshore wind projects following setbacks in the U.S. market. This coordinated effort to strengthen its balance sheet and streamline operations highlights the company’s shift to core regions after volatility in renewables markets and political challenges abroad. We’ll now explore how Ørsted’s renewed...
CPSE:CARL B
CPSE:CARL BBeverage

A Fresh Look at Carlsberg (CPSE:CARL B) Valuation After UK Soft Drinks Expansion and Poppi Deal

Carlsberg (CPSE:CARL B) has taken several steps to boost its presence in the UK soft drinks market, announcing a major investment in a new canning line at its Rugby facility. In addition to the expansion, the exclusive distribution of Poppi prebiotic soda adds a growth angle worth watching. See our latest analysis for Carlsberg. These strategic moves come as Carlsberg’s share price recently softened, with a 90-day return of -17.4%, even as the year-to-date share price return remains positive...